By Algernon Watts I’ll admit, growing up, I only thought of bees as creatures to avoid, a lesson reinforced by a few childhood stings. But as my love for f ...
Throughout the quarter, INBS announced the completion of the in-clinic portion of its FDA 510 (k) clinical study plan. An initial review of the PK study data shows that fingerprint sweat aligns ...
Novozymes and Chr. Hansen have historically generated ample free cash flow and returned value to shareholders primarily through dividends. Management expects to continue to reward shareholders with a ...